Ranosidenib

DB21727InvestigationalSmall molecule

Ranosidenib is a small molecule drug. Ranosidenib is under investigation in clinical trial NCT06387069 (A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia). Ranosidenib has... Ranosidenib has a monoisotopic molecular weight of 453.12 Da.

Mechanism: Pharmacologically active on Isocitrate dehydrogenase [NADP] cytoplasmic and Isocitrate dehydrogenase [NADP], mitochondrial
Curator reviewed
Formula / weight: C₁₅H₁₆F₉N₅O · 453.313 g/mol (avg)
Code names: HMPL-306

Resolves to

Compound

UNIIPC64OXS2C2CAS2301974-60-5ChEMBLCHEMBL6068069ChEBI759987PubChem162445339

Structure

InChIKeyCECMHVJGNAFHKN-KCRUCZTKSA-NSMILESC[C@@H](NC1=NC(=NC(N[C@H](C)C(F)(F)F)=N1)C1=C(F)[C@H](O)C(F)(F)CC1)C(F)(F)F

Targets

O75874IDH1P48735IDH2

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ranosidenib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account